<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Treatment of basal cell carcinomas at high risk for recurrence
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Treatment of basal cell carcinomas at high risk for recurrence
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Treatment of basal cell carcinomas at high risk for recurrence
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sumaira Z Aasi, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Angela M Hong, MBBS, MMed, PhD, FRANZCR
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            June K Robinson, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Robert S Stern, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Rosamaria Corona, MD, DSc
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Aug 04, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H7225556">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Basal cell carcinoma (BCC) is a common skin cancer that arises from the basal layer of the epidermis and its appendages. Treatment of BCC is indicated due to the locally invasive, aggressive, and destructive effects of BCC on skin and surrounding tissues  (
         <a class="graphic graphic_picture graphicRef68274 graphicRef81632" href="/z/d/graphic/68274.html" rel="external">
          picture 1A-B
         </a>
         ).
        </p>
        <p>
         Tumor characteristics, such as size, location, and pathology, influence the likelihood for deep tumor invasion and recurrence of BCC after treatment. Lesions at high risk for recurrence may benefit from removal with surgical procedures that allow for complete peripheral and deep margin assessment, such as Mohs micrographic surgery (MMS) and staged excision with circumferential margin assessment. Alternative therapies include conventional surgical excision and radiation therapy (RT).
        </p>
        <p>
         The treatment of BCCs with clinical or pathologic features associated with increased risk for recurrence will be reviewed here. The risk factors, clinical manifestations, and prognosis of BCC, as well as the management of less aggressive BCCs, are reviewed separately. The management of locally advanced and metastatic BCC is also discussed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5335.html" rel="external">
          "Basal cell carcinoma: Epidemiology, pathogenesis, clinical features, and diagnosis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5338.html" rel="external">
          "Treatment and prognosis of basal cell carcinoma at low risk of recurrence"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7619.html" rel="external">
          "Systemic treatment of advanced basal cell and cutaneous squamous cell carcinomas not amenable to local therapies"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H12329758">
         <span class="h1">
          FEATURES ASSOCIATED WITH HIGH RISK FOR RECURRENCE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Certain clinical and pathologic features of basal cell carcinoma (BCC) are associated with an elevated risk for recurrence after treatment. Recurrent BCC may reappear months to years after initial treatment, leading to local tissue destruction, morbidity, increased risk for metastasis, and the need for retreatment  (
         <a class="graphic graphic_picture graphicRef68274 graphicRef81632" href="/z/d/graphic/68274.html" rel="external">
          picture 1A-B
         </a>
         ).
        </p>
        <p>
         The following characteristics have been proposed as factors associated with increased risk for tumor recurrence in the 2021 National Comprehensive Cancer Network (NCCN) clinical practice guidelines on cutaneous BCC. The presence of
         <strong>
          any
         </strong>
         of these factors places the tumor in the high-risk category [
         <a href="#rid1">
          1
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Tumors of
         <strong>
          any size
         </strong>
         on the head and neck, including:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Tumors on the "mask area" of the face (ie, nose, lips, eyelids, eyebrows, periorbital skin, chin, mandible, ears, preauricular and postauricular areas, temples  (
         <a class="graphic graphic_figure graphicRef103749" href="/z/d/graphic/103749.html" rel="external">
          figure 1
         </a>
         ))
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Tumors on nonmask area of the face (ie, cheeks, forehead  (
         <a class="graphic graphic_picture graphicRef127426 graphicRef127427" href="/z/d/graphic/127426.html" rel="external">
          picture 2A-B
         </a>
         ))
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Tumors on neck and scalp
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Tumors on hands, feet, and genitalia
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Tumors
         <strong>
          ≥20 mm
         </strong>
         in diameter on trunk and extremities, excluding hands and feet
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lesions with poorly defined borders
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Recurrent lesions
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lesions in sites of prior radiation therapy (RT)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Aggressive pathologic features:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Micronodular, morpheaform, sclerosing, or mixed infiltrative  (
         <a class="graphic graphic_picture graphicRef56527" href="/z/d/graphic/56527.html" rel="external">
          picture 3
         </a>
         )
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Basosquamous (keratinizing) or carcinosarcomatous
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Perineural invasion
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Immunocompromised patient (eg, solid organ and hematopoietic cell transplant recipients; patients with immune deficiencies, including congenital disorders and HIV/AIDS, and autoimmune disorders; patients treated with immunosuppressive therapies; cancer patients on immunotherapies or checkpoint inhibitors)
        </p>
        <p>
        </p>
        <p>
         The designation of tumor location and size as important determinants for the selection of appropriate treatment is based upon the following factors:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Many areas on the face represent embryologic cleavage planes; these sites provide relatively little resistance to tumor invasion.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         High-risk sites often have a high density of hair follicles and sebaceous glands. The physical presence of these structures makes eradication of tumors with curettage and electrodesiccation (C&amp;E) and nonsurgical therapies less reliable.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Involvement of critical structures, such as the eyelid, or cosmetically sensitive areas makes complete tumor removal without cosmetic or functional impairment difficult.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Large tumors may have extensive subclinical growth, requiring wider excisional margins for disease clearance and accounting for lower rates of response to destructive therapies.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H765272281">
         <span class="h1">
          APPROACH TO MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Our approach to the management of high-risk basal cell carcinoma (BCC) is generally consistent with published guidelines  (
         <a class="graphic graphic_algorithm graphicRef134218" href="/z/d/graphic/134218.html" rel="external">
          algorithm 1
         </a>
         ) [
         <a href="#rid1">
          1-3
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mohs micrographic surgery (MMS) and staged excision with complete circumferential peripheral and deep margin assessment (CCPDMA) are the preferred treatments for BCCs at high risk for recurrence, in particular for tumors on the head and neck, hands and feet, pretibia, and genitalia [
         <a href="#rid2">
          2,4-9
         </a>
         ]. MMS is a specialized surgical technique that uses intraoperative frozen horizontal sections and allows for the histologic evaluation of the entire peripheral and deep margins of the tumor while minimizing the amount of normal tissue that must be resected [
         <a href="#rid10">
          10
         </a>
         ] (see
         <a class="medical medical_review" href="/z/d/html/13708.html" rel="external">
          "Mohs surgery"
         </a>
         ). Staged excision with CCPDMA allows complete assessment of tissue margins utilizing formalin-fixed tissue, rather than the rapidly processed frozen sections used in standard Mohs surgery.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Alternative options for the treatment of high-risk lesions include standard surgical excision and radiation therapy (RT). Both options have advantages and disadvantages  (
         <a class="graphic graphic_table graphicRef70043" href="/z/d/graphic/70043.html" rel="external">
          table 1
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Standard surgical excision has long-term recurrence rates higher than MMS [
         <a href="#rid11">
          11
         </a>
         ] and provides pathologic assessment of only a small fraction of the excisional margin (estimated to be &lt;1 percent) but is faster, less expensive, and more widely available than MMS. (See
         <a class="local">
          'Standard surgical excision'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         RT is an important treatment option for older patients with high-risk BCC who are not surgical candidates. Disadvantages of RT include a lower cure rate, the need for multiple clinic visits, high cost, and potential risk for long-term adverse effects. (See
         <a class="local">
          'Primary radiation therapy'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Curettage and electrodesiccation (C&amp;E) should
         <strong>
          not
         </strong>
         be used for the treatment of most lesions with more aggressive clinical or pathologic features, although it can achieve high cure rates for primary BCCs at low risk for recurrence located on the trunk or extremities [
         <a href="#rid12">
          12-14
         </a>
         ]. Topical therapies and photodynamic therapy (PDT) should
         <strong>
          not
         </strong>
         be used for the treatment of high-risk BCC as well.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H402953042">
         <span class="h1">
          SURGICAL CANDIDATES
         </span>
        </p>
        <p class="headingAnchor" id="H12329803">
         <span class="h2">
          Mohs micrographic surgery
         </span>
         <span class="headingEndMark">
          —
         </span>
         For the treatment of basal cell carcinoma (BCC) at high risk of recurrence, we suggest Mohs micrographic surgery (MMS), if available, as first-line therapy for tumors of any size on high-risk areas of the face ("mask area"  (
         <a class="graphic graphic_figure graphicRef103749" href="/z/d/graphic/103749.html" rel="external">
          figure 1
         </a>
         )), on nonmask areas of the face (ie, cheeks, forehead), scalp, pretibia, hands, feet, and genitalia  (
         <a class="graphic graphic_algorithm graphicRef134218" href="/z/d/graphic/134218.html" rel="external">
          algorithm 1
         </a>
         ) [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p>
         MMS allows for the control of 100 percent of the tumor margins while minimizing the resection of normal tissue. Even for small tumors, MMS allows for the identification of inapparent tumor extensions while maximizing normal tissue sparing (see
         <a class="medical medical_review" href="/z/d/html/13708.html" rel="external">
          "Mohs surgery"
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
         – One randomized trial with an extended follow-up and several large case series support the long-term efficacy of MMS for the treatment of high-risk BCC [
         <a href="#rid7">
          7,8,11,16-18
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         One randomized trial compared standard excision with MMS for the treatment of 408 primary, high-risk, facial BCCs and 204 recurrent, facial BCCs [
         <a href="#rid7">
          7
         </a>
         ]. At the 30-month follow-up, the recurrence rates were 2 and 3 percent for primary BCCs treated with MMS and standard excision, respectively, and 0 and 3 percent for recurrent BCCs treated with MMS and standard excision, respectively. However, in an extended follow-up study of the same cohort, the 10-year recurrence rates were lower in the MMS group than in the standard excision group for primary BCCs (4.4 percent [95% CI 1.9-9.8] versus 12.2 percent [95% CI 7.3-19.8], respectively) as well as for recurrent tumors (3.9 percent [95% CI 1.3-11.7] versus 13.5 percent [95% CI 7.6-23.2], respectively) [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a large, Australian series of 819 patients with periocular BCCs treated with MMS, among the 346 patients who had strict, five-year follow-up, seven (2 percent) had recurrences [
         <a href="#rid16">
          16
         </a>
         ]. All recurrences occurred in a subgroup of 90 previously recurrent tumors (with up to three recurrences before MMS), whereas no recurrences occurred in the primary BCC group.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The recurrence rate after Mohs surgery appears to be higher for lesions with histologic evidence for perineural invasion. In a series of 3020 patients with BCC (including 78 patients with BCCs with perineural invasion), five-year recurrence rates for patients with or without perineural invasion were 8 and 2 percent, respectively [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Disadvantages of Mohs micrographic surgery
         </strong>
         – Disadvantages of Mohs micrographic surgery (MMS) include duration and costs. A typical MMS procedure may last a few hours, and more complicated cases can take longer. Reconstruction following MMS may be performed the same day or at a subsequent time, depending on the anticipated length of the repair. A significant amount of the total time is spent with the histologic preparation and analysis; during this time, patients are temporarily bandaged and may await the final results in a waiting room. A small minority of patients may find it difficult to tolerate a procedure of this length.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         MMS is more expensive than standard, office-based surgical excision and is more expensive than excision with intraoperative frozen sections in an operating room. Whether MMS is cost effective remains controversial, as some studies do not factor in the cost of retreating tumors that recur [
         <a href="#rid20">
          20-23
         </a>
         ], and cost determination and accounting for surgery differs considerably among countries.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2767492689">
         <span class="h2">
          Staged excision with circumferential margin assessment
         </span>
         <span class="headingEndMark">
          —
         </span>
         Staged excision with complete circumferential peripheral and deep margin assessment (CCPDMA) is an alternative to MMS for high-risk BCCs. It involves complete assessment of tissue margins utilizing formalin-fixed tissue, rather than the rapidly processed frozen sections used in standard MMS. This procedure is performed without the equipment and technician expertise required for frozen tissue processing (see
         <a class="medical medical_review" href="/z/d/html/13708.html" rel="external">
          "Mohs surgery", section on 'Surgical technique'
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
         – In large series of BCCs including periocular and recurrent tumors, staged excision with CCPDMA was associated with five-year cure rates of 97 to 99 percent [
         <a href="#rid24">
          24-26
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Disadvantages
         </strong>
         – The time required to attain pathology results from formalin-fixed tissue specimens delays wound closure for days and leads to the need for repeat office visits. Thus, the procedure is less desirable than MMS for some patients.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3313511164">
         <span class="h2">
          Standard surgical excision
         </span>
         <span class="headingEndMark">
          —
         </span>
         Standard excision with postoperative margin assessment is a treatment option for select high-risk tumors on the trunk and extremities (except the hands and feet).
        </p>
        <p>
         There are no data from randomized trials addressing the appropriate margin size for high-risk BCC. However, it is recommended to use margins wider than 4 to 5 mm (deemed to be appropriate for low-risk BCC), as feasible, depending on the specific location of the tumor [
         <a href="#rid1">
          1
         </a>
         ]. This recommendation is supported by indirect evidence from observational studies using MMS and randomized trials evaluating the efficacy of standard surgical excision compared with other treatment modalities:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In an observational study of 306 patients with facial BCCs (approximately 90 percent in the mask area and with micronodular or infiltrative histology) excised with MMS, complete excision was obtained in 74 percent of tumors with 2 mm margins, in 94 percent of tumors with 3 mm margins, and in 99 percent of tumors with 4 mm margins [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a 2010 meta-analysis of 37 studies, most of which were observational, the analysis of pooled data from 10,261 patients with 16,066 nodular BCCs treated with surgical excision found that the mean recurrence rates for BCCs excised with 5, 4, 3, and 2 mm surgical margins were 0.4, 1.6, 2.6, and 4 percent, respectively [
         <a href="#rid28">
          28
         </a>
         ]. The rates of pathologically confirmed complete excisions were similar for surgical margins between 3 and 5 mm.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A randomized trial compared standard surgical excision with Mohs surgery for the treatment of 408 primary, high-risk, facial BCCs [
         <a href="#rid7">
          7
         </a>
         ]. Tumors assigned to standard excision were excised with 3 mm margins and, if incompletely excised, re-excised with 3 mm margins. In cases of two incomplete excisions, tumors were treated with MMS. At 30 months, the recurrence rates were similar in the standard excision and MMS groups (3 and 2 percent, respectively). Two extended, follow-up studies of the same cohort found 5- and 10-year recurrence rates of 4 and 12 percent, respectively, in the standard excision group and 2.5 and 4.4 percent, respectively, in the Mohs surgery group [
         <a href="#rid8">
          8,11
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1963376128">
         <span class="h1">
          NONSURGICAL CANDIDATES
         </span>
        </p>
        <p class="headingAnchor" id="H12329838">
         <span class="h2">
          Primary radiation therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with high-risk basal cell carcinoma (BCC) who are not surgical candidates (eg, older patients, patients with multiple comorbidities who may not tolerate surgery, patients who decline surgery), primary radiation therapy (RT) is the preferred alternative treatment option  (
         <a class="graphic graphic_algorithm graphicRef134218" href="/z/d/graphic/134218.html" rel="external">
          algorithm 1
         </a>
         ) [
         <a href="#rid29">
          29
         </a>
         ]. External beam RT is usually administered in a fractionated schedule that requires treatments on consecutive weekdays for four or more weeks.
        </p>
        <p>
         Fractionation limits treatment-related late effects in normal tissues, but the frequent visits may be problematic for many patients. Hypofractionated regimens, with higher doses per fraction delivered one to three times per week for two to three weeks, appear to be more acceptable to older and frail patients despite an increased risk of late adverse effects [
         <a href="#rid30">
          30
         </a>
         ].
        </p>
        <p>
         RT should be considered a treatment of last resort for previously irradiated, recurrent BCCs because of the risk of cumulative radiation toxicity [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H989294820">
         <span class="h3">
          Efficacy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most large series report overall five-year cure rates of 91 to 93 percent for previously untreated BCCs, with rates as high as 96 percent for smaller BCCs at low risk for recurrence [
         <a href="#rid32">
          32-34
         </a>
         ]. For patients with recurrent BCCs, the reported cure rates are somewhat lower, generally between 86 and 91 percent [
         <a href="#rid32">
          32-35
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the only randomized trial comparing surgery with radiotherapy in 347 patients with facial BCC &lt;40 mm, the primary endpoint was the failure rate (persistent or recurrent disease) after four years of follow-up. Of the 173 patients in the radiotherapy group, 55 percent were treated with interstitial brachytherapy, 33 percent were treated with contact brachytherapy, and 12 percent were treated with conventional radiotherapy. The four-year recurrence rate was 0.7 percent (95% CI 0.1-3.9) in the surgery group and 7.5 percent (95% CI 4.2-13.1) in the radiotherapy group [
         <a href="#rid36">
          36
         </a>
         ]. More patients in the surgery group than in the radiotherapy group were satisfied with the cosmetic results. Eighty-seven percent of the surgery-treated patients and 69 percent of the radiation-treated patients considered the cosmetic result as good (p &lt;0.01).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A systematic review and network meta-analysis of various treatments for BCC showed similar recurrence rates for standard surgery (3.3 percent, 95% CI 1.3-7.8 percent), Mohs surgery (3.8 percent, 95% CI 0.7-18.9 percent), curettage and diathermy (5.9 percent, 95% CI 0.7-34.9 percent), and radiotherapy (3.2 percent, 95% CI 0.6-16.1 percent) [
         <a href="#rid37">
          37
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         BCCs that recur following RT may behave more aggressively than those recurring after surgical procedures, with higher rates of second recurrence and distant metastasis [
         <a href="#rid38">
          38
         </a>
         ].
        </p>
        <p>
         Although early reports suggested a poor outcome with RT alone for larger or more deeply invasive tumors (ie, those involving cartilage, bone, and/or muscle), series using modern RT techniques, such as volumetric modulated arc therapy (VMAT), suggest excellent control rates with good cosmesis and functional outcomes. In several reports, three- to five-year locoregional control rates were 86 to 91 percent for large and/or locally advanced BCCs with RT [
         <a href="#rid32">
          32,34,39-42
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4123626977">
         <span class="h3">
          Advantages and disadvantages
         </span>
         <span class="headingEndMark">
          —
         </span>
         The major advantages of RT are the relative sparing of cosmetically and functionally important structures, its noninvasive and painless nature, and its utility for many patients who are not candidates for surgical intervention or for whom it is difficult to attain histologic clearance. In addition, the relative sparing of normal healthy tissue can offer superior cosmetic results for tumors located on or around the lips, nose, and eyelids. However, these favorable cosmetic results may deteriorate with time [
         <a href="#rid39">
          39,43
         </a>
         ].
        </p>
        <p>
         Disadvantages of RT include a lower cure rate compared with surgical procedures, the need for multiple clinic visits, high cost, and potential risk for long-term adverse effects. Unlike surgical excision or Mohs surgery, RT does not provide histologic control of the tumor margins. RT is considerably more expensive than other treatments and is associated with a number of short-term and long-term side effects. (See
         <a class="local">
          'Adverse events'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3201115486">
         <span class="h3">
          Contraindications
         </span>
         <span class="headingEndMark">
          —
         </span>
         RT is generally avoided for tumors located on areas of poor vascularity and wear-and-tear sites (eg, regions below the elbow or knee [pretibial region and dorsum of the hand], cartilage [ear], and bony prominences). The skin in these areas is subject to greater trauma and tension and is more prone to break down and ulcerate as a result of the atrophy and poor vascularity of irradiated tissue.
        </p>
        <p>
         RT should never be used in patients with basal cell nevus syndrome, where RT may induce numerous skin cancers that are difficult to manage (see
         <a class="medical medical_review" href="/z/d/html/5340.html" rel="external">
          "Nevoid basal cell carcinoma syndrome (Gorlin syndrome)", section on 'Risk factors for basal cell carcinoma'
         </a>
         ). In addition, RT should be avoided in younger patients due to worsening functional and cosmetic results with time and the risk of developing a secondary cancer in the treatment field.
        </p>
        <p class="headingAnchor" id="H12329852">
         <span class="h3">
          Adverse events
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most patients experience some temporary fatigue during RT. Other acute, expected side effects of RT include localized erythema and edema, scaling, and pain. Occasionally, ulceration with bleeding and infection can develop. These skin reactions tend to peak at the end of the course of RT and during the first 10 to 14 days after completion. Healing generally starts at approximately two weeks following the final fraction. (See
         <a class="medical medical_review" href="/z/d/html/13668.html" rel="external">
          "Radiation dermatitis"
         </a>
         .)
        </p>
        <p>
         Late effects of radiation within the treatment field may include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Permanent alopecia occurs within the treatment field. Patients should be advised of this prior to treatment, and pretreatment counseling is essential.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Chronic radiation dermatitis generally appears months to years following therapy and is characterized by permanently mottled areas of hypopigmentation and hyperpigmentation; a dry, hyperkeratotic, atrophic, shiny epidermis; telangiectasias; and dermal fibrosis. These are generally a cosmetic issue and rarely cause any symptoms. Patients who have received larger doses (&gt;3 to 4 Gy) per fraction are more likely to develop these changes.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Other possible late effects within the radiation field could include cataract, dry eye, and ectropion for periocular disease. These are uncommon events that should be avoided with proper shielding during therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Radiation-induced cutaneous malignancies (both BCCs and squamous cell cancers) may develop within irradiated sites [
         <a href="#rid44">
          44,45
         </a>
         ]. These secondary cancers can occur from five years to several decades following RT and are thought to behave aggressively, with a higher likelihood of subclinical extension than other skin cancers.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Risk factors for secondary cancers after RT include higher radiation doses, larger radiation fields, sun-exposed sites, fair skin, and early age of radiation exposure. Although some investigators think that the risk of radiation-induced cutaneous malignancy is theoretically smaller using modern conformal techniques to minimize the dose to the surrounding normal structures, RT continues to be avoided in young people and in those with genetic susceptibility to radiation-induced malignancies  (
         <a class="graphic graphic_table graphicRef57649" href="/z/d/graphic/57649.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid46">
          46,47
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1032209">
         <span class="h2">
          Other therapies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Photodynamic therapy (PDT) and
         <a class="drug drug_general" data-topicid="8638" href="/z/d/drug information/8638.html" rel="external">
          imiquimod
         </a>
         have been used in a few studies of patients with BCC with high-risk features. However, because data supporting these interventions for high-risk lesions are very limited, their routine use for high-risk BCCs is
         <strong>
          not
         </strong>
         recommended:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Two observational studies of
         <a class="drug drug_general" data-topicid="16481" href="/z/d/drug information/16481.html" rel="external">
          methyl aminolevulinate
         </a>
         (MAL)-PDT for patients with high-risk BCC reported recurrence rates of 18 to 24 percent at 24 months [
         <a href="#rid48">
          48,49
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a few small series of patients with eyelid BCC,
         <a class="drug drug_general" data-topicid="8638" href="/z/d/drug information/8638.html" rel="external">
          imiquimod
         </a>
         was used with variable results [
         <a href="#rid50">
          50-53
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a small, randomized trial including 27 patients with primary, nodular BCCs of the eyelid comparing
         <a class="drug drug_general" data-topicid="8638" href="/z/d/drug information/8638.html" rel="external">
          imiquimod
         </a>
         with RT, both treatments were effective in inducing histopathologic remission at 3 months and sustained clinical remission at 24 months [
         <a href="#rid54">
          54
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         The use of PDT and
         <a class="drug drug_general" data-topicid="8638" href="/z/d/drug information/8638.html" rel="external">
          imiquimod
         </a>
         for low-risk BCC is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/5338.html" rel="external">
          "Treatment and prognosis of basal cell carcinoma at low risk of recurrence", section on 'Imiquimod'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5338.html" rel="external">
          "Treatment and prognosis of basal cell carcinoma at low risk of recurrence", section on 'Photodynamic therapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1619334555">
         <span class="h1">
          SPECIAL SITUATIONS
         </span>
        </p>
        <p class="headingAnchor" id="H488366810">
         <span class="h2">
          Tumors excised with positive margins
         </span>
         <span class="headingEndMark">
          —
         </span>
         Basal cell carcinomas (BCCs) may not be excised completely. Rates of margin positivity of 10 to 27 percent have been reported for high-risk BCCs excised with standard excision or Mohs micrographic surgery (MMS) [
         <a href="#rid55">
          55-57
         </a>
         ].
        </p>
        <p>
         In patients with positive margins after standard surgical excision, re-excision with either MMS or staged excision with complete circumferential peripheral and deep margin assessment (CCPDMA) should be performed. If clear margins cannot be achieved with either of those modalities, adjuvant radiation therapy (RT), systemic hedgehog pathway inhibitors, and multidisciplinary tumor board consultation should be considered  (
         <a class="graphic graphic_algorithm graphicRef134218" href="/z/d/graphic/134218.html" rel="external">
          algorithm 1
         </a>
         ) [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         Adjuvant RT has been used postoperatively in patients with incompletely resected tumors. In a series of 55 patients with BCC located in the head/neck region (74 percent on the face) treated with adjuvant RT after surgical excision, the recurrence rate was 3.6 percent [
         <a href="#rid58">
          58
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H880440824">
         <span class="h2">
          Recurrent tumors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Recurrent BCCs, especially those located in high-risk sites, are candidates for MMS, particularly because recurrent tumors tend to develop more aggressive histologic subtypes [
         <a href="#rid59">
          59
         </a>
         ]. In a randomized trial that included 201 recurrent, facial BCCs treated with standard excision or MMS, the recurrence rate was 3 percent after standard excision and 0 percent after MMS [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1725942728">
         <span class="h2">
          Locally advanced tumors/metastatic disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         The management of locally advanced BCC not amenable to treatment with surgery or RT with systemic therapies, including inhibitors of the hedgehog pathway (eg,
         <a class="drug drug_general" data-topicid="17142" href="/z/d/drug information/17142.html" rel="external">
          vismodegib
         </a>
         ,
         <a class="drug drug_general" data-topicid="103072" href="/z/d/drug information/103072.html" rel="external">
          sonidegib
         </a>
         ), immune checkpoint inhibitors, or chemotherapy is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/7619.html" rel="external">
          "Systemic treatment of advanced basal cell and cutaneous squamous cell carcinomas not amenable to local therapies"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H12329880">
         <span class="h1">
          PROGNOSIS AND FOLLOW-UP
         </span>
         <span class="headingEndMark">
          —
         </span>
         The prognosis for most patients with high-risk, primary basal cell carcinoma (BCC) is excellent. Metastatic disease is a very rare event, estimated to occur in 0.0029 to 0.05 percent of patients [
         <a href="#rid60">
          60-62
         </a>
         ]. Metastatic lesions usually occur in association with deeply invasive or large lesions; common sites for metastasis include the regional lymph nodes, lungs, bones, skin, and liver [
         <a href="#rid63">
          63
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/13714.html" rel="external">
          "Evaluation for locoregional and distant metastases in cutaneous squamous cell and basal cell carcinoma", section on 'Basal cell carcinoma'
         </a>
         .)
        </p>
        <p>
         Metastatic BCC generally has been considered to have a very poor prognosis. A review of 194 published cases of metastatic BCC between 1981 and 2011 found a median survival after diagnosis of metastatic disease of 10 months (range 0.5 to 108 months) [
         <a href="#rid63">
          63
         </a>
         ]. However, a more favorable prognosis is suggested by a retrospective study of 10 patients evaluated at a single academic medical center between 1997 and 2011. Median overall survival following a diagnosis of metastatic BCC was 7.3 years (95% CI 1.62 to infinity) at the cut-off date of the study, with seven patients still alive at the end of the assessment period [
         <a href="#rid64">
          64
         </a>
         ]. Of note, all patients in the retrospective study received adjuvant treatment, including six who received treatment with the hedgehog pathway inhibitor
         <a class="drug drug_general" data-topicid="17142" href="/z/d/drug information/17142.html" rel="external">
          vismodegib
         </a>
         . (See
         <a class="medical medical_review" href="/z/d/html/7619.html" rel="external">
          "Systemic treatment of advanced basal cell and cutaneous squamous cell carcinomas not amenable to local therapies"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1419899915">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/120260.html" rel="external">
          "Society guideline links: Nonmelanoma skin cancer"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/123058.html" rel="external">
          "Society guideline links: Mohs surgery"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H260624">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          High-risk features
         </strong>
         – Basal cell carcinomas (BCCs) with
         <strong>
          any
         </strong>
         of the following features are considered at high risk of recurrence:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Tumors of
         <strong>
          any
         </strong>
         size on the head and neck, hands, feet, and genitalia
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Tumors
         <strong>
          ≥20 mm
         </strong>
         in diameter on trunk and extremities, excluding hands and feet
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Lesions with poorly defined borders
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Recurrent lesions
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Lesions in sites of prior radiation therapy (RT)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Aggressive pathologic features (micronodular, morpheaform, sclerosing, or mixed infiltrative, basosquamous, carcinosarcomatous)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Perineural invasion
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Immunocompromised patient
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management
         </strong>
         (
         <a class="graphic graphic_algorithm graphicRef134218" href="/z/d/graphic/134218.html" rel="external">
          algorithm 1
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For
         <strong>
          surgical candidates
         </strong>
         with high-risk BCCs of any size located on the head and neck, hands, feet, and genitalia, we suggest Mohs micrographic surgery (MMS) rather than standard surgical excision or primary RT (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Even for small tumors, MMS allows for the identification of inapparent tumor extensions while maximizing normal tissue sparing. In settings where MMS is not available, standard surgical excision with margins wider than 4 to 5 mm or staged excision with complete circumferential peripheral and deep margin assessment (CCPDMA) are alternative surgical approaches. (See
         <a class="local">
          'Surgical candidates'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients who are
         <strong>
          nonsurgical candidates
         </strong>
         (eg, older patients, patients with multiple comorbidities who may not tolerate surgery, patients who decline surgery), we suggest primary RT rather than photodynamic therapy (PDT) or
         <a class="drug drug_general" data-topicid="8638" href="/z/d/drug information/8638.html" rel="external">
          imiquimod
         </a>
         (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). RT is contraindicated for tumors located on areas of poor vascularity; in younger patients, due to worsening functional and cosmetic results with time; and in patients with Gorlin syndrome, as RT can increase the risk of developing further BCCs. (See
         <a class="local">
          'Nonsurgical candidates'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The management of locally advanced BCC not amenable to treatment with surgery or RT with systemic therapies is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7619.html" rel="external">
          "Systemic treatment of advanced basal cell and cutaneous squamous cell carcinomas not amenable to local therapies"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H443275219">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Timothy K Chartier, MD (deceased), who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Basal cell skin cancer. Version 2.2021. https://www.nccn.org/professionals/physician_gls/pdf/nmsc.pdf (Accessed on August 13, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peris K, Fargnoli MC, Garbe C, et al. Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines. Eur J Cancer 2019; 118:10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nasr I, McGrath EJ, Harwood CA, et al. British Association of Dermatologists guidelines for the management of adults with basal cell carcinoma 2021. Br J Dermatol 2021; 185:899.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Work Group, Invited Reviewers, Kim JYS, et al. Guidelines of care for the management of basal cell carcinoma. J Am Acad Dermatol 2018; 78:540.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rowe DE, Carroll RJ, Day CL Jr. Mohs surgery is the treatment of choice for recurrent (previously treated) basal cell carcinoma. J Dermatol Surg Oncol 1989; 15:424.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leibovitch I, Huilgol SC, Selva D, et al. Basal cell carcinoma treated with Mohs surgery in Australia II. Outcome at 5-year follow-up. J Am Acad Dermatol 2005; 53:452.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smeets NW, Krekels GA, Ostertag JU, et al. Surgical excision vs Mohs' micrographic surgery for basal-cell carcinoma of the face: randomised controlled trial. Lancet 2004; 364:1766.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mosterd K, Krekels GA, Nieman FH, et al. Surgical excision versus Mohs' micrographic surgery for primary and recurrent basal-cell carcinoma of the face: a prospective randomised controlled trial with 5-years' follow-up. Lancet Oncol 2008; 9:1149.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thomson J, Hogan S, Leonardi-Bee J, et al. Interventions for basal cell carcinoma: abridged Cochrane systematic review and GRADE assessments. Br J Dermatol 2021; 185:499.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muller FM, Dawe RS, Moseley H, Fleming CJ. Randomized comparison of Mohs micrographic surgery and surgical excision for small nodular basal cell carcinoma: tissue-sparing outcome. Dermatol Surg 2009; 35:1349.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Loo E, Mosterd K, Krekels GA, et al. Surgical excision versus Mohs' micrographic surgery for basal cell carcinoma of the face: A randomised clinical trial with 10 year follow-up. Eur J Cancer 2014; 50:3011.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salasche SJ. Curettage and electrodesiccation in the treatment of midfacial basal cell epithelioma. J Am Acad Dermatol 1983; 8:496.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suhge d'Aubermont PC, Bennett RG. Failure of curettage and electrodesiccation for removal of basal cell carcinoma. Arch Dermatol 1984; 120:1456.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Silverman MK, Kopf AW, Grin CM, et al. Recurrence rates of treated basal cell carcinomas. Part 2: Curettage-electrodesiccation. J Dermatol Surg Oncol 1991; 17:720.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ad Hoc Task Force, Connolly SM, Baker DR, et al. AAD/ACMS/ASDSA/ASMS 2012 appropriate use criteria for Mohs micrographic surgery: a report of the American Academy of Dermatology, American College of Mohs Surgery, American Society for Dermatologic Surgery Association, and the American Society for Mohs Surgery. J Am Acad Dermatol 2012; 67:531.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malhotra R, Huilgol SC, Huynh NT, Selva D. The Australian Mohs database, part II: periocular basal cell carcinoma outcome at 5-year follow-up. Ophthalmology 2004; 111:631.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sin CW, Barua A, Cook A. Recurrence rates of periocular basal cell carcinoma following Mohs micrographic surgery: a retrospective study. Int J Dermatol 2016; 55:1044.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paoli J, Daryoni S, Wennberg AM, et al. 5-year recurrence rates of Mohs micrographic surgery for aggressive and recurrent facial basal cell carcinoma. Acta Derm Venereol 2011; 91:689.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leibovitch I, Huilgol SC, Selva D, et al. Basal cell carcinoma treated with Mohs surgery in Australia III. Perineural invasion. J Am Acad Dermatol 2005; 53:458.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chren MM. Determining the value of surgical therapies for basal cell carcinoma. Arch Dermatol 2006; 142:231.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cook J, Zitelli JA. Mohs micrographic surgery: a cost analysis. J Am Acad Dermatol 1998; 39:698.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Essers BA, Dirksen CD, Nieman FH, et al. Cost-effectiveness of Mohs Micrographic Surgery vs Surgical Excision for Basal Cell Carcinoma of the Face. Arch Dermatol 2006; 142:187.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sebaratnam DF, Choy B, Lee M, et al. Direct Cost-Analysis of Mohs Micrographic Surgery and Traditional Excision for Basal Cell Carcinoma at Initial Margin Clearance. Dermatol Surg 2016; 42:633.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lawrence CM, Haniffa M, Dahl MG. Formalin-fixed tissue Mohs surgery (slow Mohs) for basal cell carcinoma: 5-year follow-up data. Br J Dermatol 2009; 160:573.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morris DS, Elzaridi E, Clarke L, et al. Periocular basal cell carcinoma: 5-year outcome following Slow Mohs surgery with formalin-fixed paraffin-embedded sections and delayed closure. Br J Ophthalmol 2009; 93:474.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wetzig T, Woitek M, Eichhorn K, et al. Surgical excision of basal cell carcinoma with complete margin control: outcome at 5-year follow-up. Dermatology 2010; 220:363.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ariza SA, Calderón DC, Aristizábal JC, Parra-Medina R. How Wide Should the Excision Margins for Facial Small Aggressive Basal Cell Carcinoma Be? Experience With 306 Cases. Dermatol Surg 2020; 46:753.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gulleth Y, Goldberg N, Silverman RP, Gastman BR. What is the best surgical margin for a Basal cell carcinoma: a meta-analysis of the literature. Plast Reconstr Surg 2010; 126:1222.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Likhacheva A, Awan M, Barker CA, et al. Definitive and Postoperative Radiation Therapy for Basal and Squamous Cell Cancers of the Skin: Executive Summary of an American Society for Radiation Oncology Clinical Practice Guideline. Pract Radiat Oncol 2020; 10:8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gunaratne DA, Veness MJ. Efficacy of hypofractionated radiotherapy in patients with non-melanoma skin cancer: Results of a systematic review. J Med Imaging Radiat Oncol 2018; 62:401.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chao CK, Gerber RM, Perez CA. Reirradiation of recurrent skin cancer of the face. A successful salvage modality. Cancer 1995; 75:2351.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Silverman MK, Kopf AW, Gladstein AH, et al. Recurrence rates of treated basal cell carcinomas. Part 4: X-ray therapy. J Dermatol Surg Oncol 1992; 18:549.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rowe DE, Carroll RJ, Day CL Jr. Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: implications for patient follow-up. J Dermatol Surg Oncol 1989; 15:315.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Locke J, Karimpour S, Young G, et al. Radiotherapy for epithelial skin cancer. Int J Radiat Oncol Biol Phys 2001; 51:748.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilder RB, Shimm DS, Kittelson JM, et al. Recurrent basal cell carcinoma treated with radiation therapy. Arch Dermatol 1991; 127:1668.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Avril MF, Auperin A, Margulis A, et al. Basal cell carcinoma of the face: surgery or radiotherapy? Results of a randomized study. Br J Cancer 1997; 76:100.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Drucker AM, Adam GP, Rofeberg V, et al. Treatments of Primary Basal Cell Carcinoma of the Skin: A Systematic Review and Network Meta-analysis. Ann Intern Med 2018; 169:456.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fleming ID, Amonette R, Monaghan T, Fleming MD. Principles of management of basal and squamous cell carcinoma of the skin. Cancer 1995; 75:699.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lovett RD, Perez CA, Shapiro SJ, Garcia DM. External irradiation of epithelial skin cancer. Int J Radiat Oncol Biol Phys 1990; 19:235.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kwan W, Wilson D, Moravan V. Radiotherapy for locally advanced basal cell and squamous cell carcinomas of the skin. Int J Radiat Oncol Biol Phys 2004; 60:406.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Caccialanza M, Piccinno R, Beretta M, Gnecchi L. Results and side effects of dermatologic radiotherapy: a retrospective study of irradiated cutaneous epithelial neoplasms. J Am Acad Dermatol 1999; 41:589.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Griep C, Davelaar J, Scholten AN, et al. Electron beam therapy is not inferior to superficial x-ray therapy in the treatment of skin carcinoma. Int J Radiat Oncol Biol Phys 1995; 32:1347.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Petit JY, Avril MF, Margulis A, et al. Evaluation of cosmetic results of a randomized trial comparing surgery and radiotherapy in the treatment of basal cell carcinoma of the face. Plast Reconstr Surg 2000; 105:2544.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karagas MR, McDonald JA, Greenberg ER, et al. Risk of basal cell and squamous cell skin cancers after ionizing radiation therapy. For The Skin Cancer Prevention Study Group. J Natl Cancer Inst 1996; 88:1848.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Deutsch A, Balagula Y, McLellan BN. Anticancer therapies associated with secondary cutaneous malignancies: A review of the literature. J Am Acad Dermatol 2020; 83:1425.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldschmidt H, Breneman JC, Breneman DL. Ionizing radiation therapy in dermatology. J Am Acad Dermatol 1994; 30:157.
          </a>
         </li>
         <li class="breakAll">
          Malkinson FD. Radiobiology of the skin. In: Fitzpatrick's Dermatology in General Medicine, 5th ed, Freedberg IM, Eisen AZ, Wolff K, et al (Eds), McGraw-Hill, 1999. Vol 1, p.1514.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vinciullo C, Elliott T, Francis D, et al. Photodynamic therapy with topical methyl aminolaevulinate for 'difficult-to-treat' basal cell carcinoma. Br J Dermatol 2005; 152:765.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Horn M, Wolf P, Wulf HC, et al. Topical methyl aminolaevulinate photodynamic therapy in patients with basal cell carcinoma prone to complications and poor cosmetic outcome with conventional treatment. Br J Dermatol 2003; 149:1242.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carneiro RC, de Macedo EM, Matayoshi S. Imiquimod 5% cream for the treatment of periocular Basal cell carcinoma. Ophthal Plast Reconstr Surg 2010; 26:100.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blasi MA, Giammaria D, Balestrazzi E. Immunotherapy with imiquimod 5% cream for eyelid nodular basal cell carcinoma. Am J Ophthalmol 2005; 140:1136.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leppälä J, Kaarniranta K, Uusitalo H, Kontkanen M. Imiquimod in the treatment of eyelid basal cell carcinoma. Acta Ophthalmol Scand 2007; 85:566.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Choontanom R, Thanos S, Busse H, Stupp T. Treatment of basal cell carcinoma of the eyelids with 5% topical imiquimod: a 3-year follow-up study. Graefes Arch Clin Exp Ophthalmol 2007; 245:1217.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garcia-Martin E, Gil-Arribas LM, Idoipe M, et al. Comparison of imiquimod 5% cream versus radiotherapy as treatment for eyelid basal cell carcinoma. Br J Ophthalmol 2011; 95:1393.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kappelin J, Nielsen K, Nilsson F, et al. Surgical treatment of basal cell carcinoma: a case series on factors influencing the risk of an incomplete primary excision. J Eur Acad Dermatol Venereol 2020; 34:2518.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ceder H, Ekström A, Hadzic L, Paoli J. Clinicopathological Factors Associated with Incomplete Excision of High-risk Basal Cell Carcinoma. Acta Derm Venereol 2021; 101:adv00496.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gąsiorowski K, Iwulska K, Zapała J, Wyszyńska-Pawelec G. Periocular basal cell carcinoma: recurrence risk factors/when to reoperate? Postepy Dermatol Alergol 2020; 37:927.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Visch Marjolein Birgitte MB, Kreike Bas B, Gerritsen Marie-Jeanne Pieternel MJP. Long-term experience with radiotherapy for the treatment of non-melanoma skin cancer. J Dermatolog Treat 2020; 31:290.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boulinguez S, Grison-Tabone C, Lamant L, et al. Histological evolution of recurrent basal cell carcinoma and therapeutic implications for incompletely excised lesions. Br J Dermatol 2004; 151:623.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           von Domarus H, Stevens PJ. Metastatic basal cell carcinoma. Report of five cases and review of 170 cases in the literature. J Am Acad Dermatol 1984; 10:1043.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weinstock MA, Bogaars HA, Ashley M, et al. Nonmelanoma skin cancer mortality. A population-based study. Arch Dermatol 1991; 127:1194.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Furlan K, Reddy V, Alabkaa A, et al. Metastatic head and neck cutaneous basal cell carcinomas: a retrospective observational study. Arch Dermatol Res 2021; 313:439.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wysong A, Aasi SZ, Tang JY. Update on metastatic basal cell carcinoma: a summary of published cases from 1981 through 2011. JAMA Dermatol 2013; 149:615.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Danial C, Lingala B, Balise R, et al. Markedly improved overall survival in 10 consecutive patients with metastatic basal cell carcinoma. Br J Dermatol 2013; 169:673.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 13724 Version 24.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://www.nccn.org/professionals/physician_gls/pdf/nmsc.pdf" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Basal cell skin cancer. Version 2.2021. https://www.nccn.org/professionals/physician_gls/pdf/nmsc.pdf (Accessed on August 13, 2021).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31288208" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34050920" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : British Association of Dermatologists guidelines for the management of adults with basal cell carcinoma 2021.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29331385" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Guidelines of care for the management of basal cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2925988" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Mohs surgery is the treatment of choice for recurrent (previously treated) basal cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16112352" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Basal cell carcinoma treated with Mohs surgery in Australia II. Outcome at 5-year follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15541449" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Surgical excision vs Mohs' micrographic surgery for basal-cell carcinoma of the face: randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19010733" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Surgical excision versus Mohs' micrographic surgery for primary and recurrent basal-cell carcinoma of the face: a prospective randomised controlled trial with 5-years' follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33448328" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Interventions for basal cell carcinoma: abridged Cochrane systematic review and GRADE assessments.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19500127" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Randomized comparison of Mohs micrographic surgery and surgical excision for small nodular basal cell carcinoma: tissue-sparing outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25262378" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Surgical excision versus Mohs' micrographic surgery for basal cell carcinoma of the face: A randomised clinical trial with 10 year follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6853782" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Curettage and electrodesiccation in the treatment of midfacial basal cell epithelioma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6497413" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Failure of curettage and electrodesiccation for removal of basal cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1820764" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Recurrence rates of treated basal cell carcinomas. Part 2: Curettage-electrodesiccation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22959232" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : AAD/ACMS/ASDSA/ASMS 2012 appropriate use criteria for Mohs micrographic surgery: a report of the American Academy of Dermatology, American College of Mohs Surgery, American Society for Dermatologic Surgery Association, and the American Society for Mohs Surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15051193" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : The Australian Mohs database, part II: periocular basal cell carcinoma outcome at 5-year follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27152747" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Recurrence rates of periocular basal cell carcinoma following Mohs micrographic surgery: a retrospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21681360" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : 5-year recurrence rates of Mohs micrographic surgery for aggressive and recurrent facial basal cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16112353" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Basal cell carcinoma treated with Mohs surgery in Australia III. Perineural invasion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16490852" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Determining the value of surgical therapies for basal cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9810885" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Mohs micrographic surgery: a cost analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16490846" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Cost-effectiveness of Mohs Micrographic Surgery vs Surgical Excision for Basal Cell Carcinoma of the Face.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27110895" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Direct Cost-Analysis of Mohs Micrographic Surgery and Traditional Excision for Basal Cell Carcinoma at Initial Margin Clearance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19210500" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Formalin-fixed tissue Mohs surgery (slow Mohs) for basal cell carcinoma: 5-year follow-up data.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19060015" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Periocular basal cell carcinoma: 5-year outcome following Slow Mohs surgery with formalin-fixed paraffin-embedded sections and delayed closure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20484877" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Surgical excision of basal cell carcinoma with complete margin control: outcome at 5-year follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31567587" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : How Wide Should the Excision Margins for Facial Small Aggressive Basal Cell Carcinoma Be? Experience With 306 Cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20885244" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : What is the best surgical margin for a Basal cell carcinoma: a meta-analysis of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31831330" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Definitive and Postoperative Radiation Therapy for Basal and Squamous Cell Cancers of the Skin: Executive Summary of an American Society for Radiation Oncology Clinical Practice Guideline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29524319" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Efficacy of hypofractionated radiotherapy in patients with non-melanoma skin cancer: Results of a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7712447" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Reirradiation of recurrent skin cancer of the face. A successful salvage modality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1624628" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Recurrence rates of treated basal cell carcinomas. Part 4: X-ray therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2646336" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: implications for patient follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11697321" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Radiotherapy for epithelial skin cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1952970" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Recurrent basal cell carcinoma treated with radiation therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9218740" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Basal cell carcinoma of the face: surgery or radiotherapy? Results of a randomized study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30242379" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Treatments of Primary Basal Cell Carcinoma of the Skin: A Systematic Review and Network Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7804997" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Principles of management of basal and squamous cell carcinoma of the skin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2394605" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : External irradiation of epithelial skin cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15380573" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Radiotherapy for locally advanced basal cell and squamous cell carcinomas of the skin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10495382" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Results and side effects of dermatologic radiotherapy: a retrospective study of irradiated cutaneous epithelial neoplasms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7635774" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Electron beam therapy is not inferior to superficial x-ray therapy in the treatment of skin carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10845311" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Evaluation of cosmetic results of a randomized trial comparing surgery and radiotherapy in the treatment of basal cell carcinoma of the face.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8961975" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Risk of basal cell and squamous cell skin cancers after ionizing radiation therapy. For The Skin Cancer Prevention Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32334055" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Anticancer therapies associated with secondary cutaneous malignancies: A review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8288778" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Ionizing radiation therapy in dermatology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8288778" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Ionizing radiation therapy in dermatology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15840111" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Photodynamic therapy with topical methyl aminolaevulinate for 'difficult-to-treat' basal cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14674903" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Topical methyl aminolaevulinate photodynamic therapy in patients with basal cell carcinoma prone to complications and poor cosmetic outcome with conventional treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20305508" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Imiquimod 5% cream for the treatment of periocular Basal cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16376667" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Immunotherapy with imiquimod 5% cream for eyelid nodular basal cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17376190" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Imiquimod in the treatment of eyelid basal cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17345092" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Treatment of basal cell carcinoma of the eyelids with 5% topical imiquimod: a 3-year follow-up study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21242584" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Comparison of imiquimod 5% cream versus radiotherapy as treatment for eyelid basal cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32124503" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Surgical treatment of basal cell carcinoma: a case series on factors influencing the risk of an incomplete primary excision.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34184066" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Clinicopathological Factors Associated with Incomplete Excision of High-risk Basal Cell Carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33603611" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Periocular basal cell carcinoma: recurrence risk factors/when to reoperate?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30892970" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Long-term experience with radiotherapy for the treatment of non-melanoma skin cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15377349" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Histological evolution of recurrent basal cell carcinoma and therapeutic implications for incompletely excised lesions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6736323" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Metastatic basal cell carcinoma. Report of five cases and review of 170 cases in the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1863078" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Nonmelanoma skin cancer mortality. A population-based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32776227" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Metastatic head and neck cutaneous basal cell carcinomas: a retrospective observational study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23677097" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Update on metastatic basal cell carcinoma: a summary of published cases from 1981 through 2011.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23521172" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Markedly improved overall survival in 10 consecutive patients with metastatic basal cell carcinoma.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
